Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash & Equivalents (2021 - 2025)

Bioregenx's Cash & Equivalents history spans 5 years, with the latest figure at $69383.0 for Q4 2025.

  • Quarterly results put Cash & Equivalents at $69383.0 for Q4 2025, up 18.8% from a year ago — trailing twelve months through Dec 2025 was $69383.0 (up 18.8% YoY), and the annual figure for FY2025 was $69383.0, up 18.8%.
  • Cash & Equivalents for Q4 2025 was $69383.0 at Bioregenx, up from $46947.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $125402.0 in Q4 2023 to a low of $676.0 in Q4 2022.
  • The 5-year median for Cash & Equivalents is $46947.0 (2025), against an average of $46983.0.
  • The sharpest move saw Cash & Equivalents tumbled 97.22% in 2022, then skyrocketed 18450.59% in 2023.
  • Year by year, Cash & Equivalents stood at $24358.0 in 2021, then tumbled by 97.22% to $676.0 in 2022, then skyrocketed by 18450.59% to $125402.0 in 2023, then tumbled by 53.43% to $58404.0 in 2024, then grew by 18.8% to $69383.0 in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $69383.0, $46947.0, and $46456.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.